THE DEAL, AT A GLANCE
1/4 reviewedKymaThera
KymaTheraKymaThera raised $80M Series B, announced 2026-10-06
01Who is involvedBacked by CapitalG, previous investors like Goldman Sachs, Summerfield Capital ManagementFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedKymaThera raised $80M Series B, announced 2026-10-06From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersIts drug-discovery work is backed by a team with prior approved cancer and serious-disease medicines.Interpretation · Explore ↗
Checked 2026-10-06 · Review due 2026-10-13
Read supporting source ↗The accomplished research team has…
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
KymaThera · Financing Record
Explore source-linked visual explanations for KymaThera. Unsupported claims are withheld while source review continues.
Record 13502 · Recorded date: 2026-10-06
Explore company records →